American Journal of Clinical Oncology

Journal

Publication Venue For

  • Utilization of an alternative docetaxel-based intraperitoneal chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma.  42:12-16. 2019
  • Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.  41:982-985. 2018
  • Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab.  41:716-721. 2018
  • ACR appropriateness Criteria® locally advanced, high-risk prostate cancer.  40:1-10. 2017
  • Advances in the management of recurrent endometrial cancer.  38:206-212. 2015
  • ACR appropriateness criterias definitive external-beam irradiation in stage T1 and T2 prostate cancer.  37:278-288. 2014
  • A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.  31:22-28. 2008
  • Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.  30:368-376. 2007
  • Microvessel density ≥60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: Results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 trial.  30:406-419. 2007
  • Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.  28:217-222. 2005
  • Protracted radiotherapy treatment duration in medulloblastoma.  26:55-59. 2003
  • Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer.  24:556-561. 2001
  • Radiation response of Rosai-Dorfman disease presenting with involvement of the orbits.  22:526-528. 1999
  • Primary lymphoma of the breast: Breast mass as an initial symptom.  22:381-383. 1999
  • Stereotactic irradiation: Potential new treatment method for brain metastases resulting from ovarian cancer.  22:143-146. 1999
  • Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.  22:1-5. 1999
  • Extragonadal germ-cell tumors: a ten-year experience..  21:198-202. 1998
  • Secondary syringomyelia due to intramedullary spinal cord metastasis: Case report and review of literature.  20:577-579. 1997
  • A Phase II study of topotecan in patients with recurrent head and neck cancer: Identification of an active new agent.  20:298-302. 1997
  • Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer.  19:483-486. 1996
  • Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer.  17:383-386. 1994
  • A Phase I study of high-dose cisplatin, prolonged infusion 5- fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.  15:461-463. 1992
  • Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group experience.  15:61-68. 1992
  • Primary lymphoma of bone: The use of MRI in pretreatment evaluation.  12:101-105. 1989
  • Phase I-II study of cisplatin, VP-16, MGBG, mitomycin, and vinblastine with radiation therapy for non-small-cell lung cancer..  11:502-505. 1988
  • Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group trial.  10:194-195. 1987
  • Phase I-II evaluation of Razoxone (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group trial.  9:185-186. 1986
  • Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group trial.  9:187-188. 1986
  • Phase II evaluation of diaziquone in gastric and pancreatic cancers. A southeastern cancer study group trial.  9:401-402. 1986
  • Tumor burden, chemotherapy, and cell kill in osteosarcoma model.  8:89-96. 1985
  • Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.  7:517-522. 1984
  • Investigation in the role of surgery, chemotherapy, and radiation in a murine osteosarcoma model.  6:61-69. 1983
  • Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma.  5:21-27. 1982
  • Phase II trial of piperazinedione in metastatic sarcoma.  5:185-187. 1982
  • International Standard Serial Number (issn)

  • 0277-3732
  • Electronic International Standard Serial Number (eissn)

  • 1537-453X